Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Oaknin

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
European Journal of Gynaecological Oncology|March 31, 2010
Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case reportA Oaknin, M P Barretina, I Morilla
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2018
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upI Ray-Coquard, P Morice, D Lorusso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 26, 2020
SEOM clinical guidelines for cervical cancer (2019)A de Juan, A Redondo, M J Rubio, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2014
A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgeryI Vergote, A Oaknin, J-F Baurain, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 22, 2017
Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical OncologyA Oaknin, R Guarch, P Barretina, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 18, 2017
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical OncologyA Oaknin, R Guarch, P Barretina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
Investigational New Drugs|January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumorsC Massard, R Salazar, J P Armand, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 10, 2015
SEOM guidelines for cervical cancerA Oaknin, M J Rubio, A Redondo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upA González-Martín, P Harter, A Leary, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
European Journal of Gynaecological Oncology|March 31, 2010
Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case reportA Oaknin, M P Barretina, I Morilla
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2018
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upI Ray-Coquard, P Morice, D Lorusso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 26, 2020
SEOM clinical guidelines for cervical cancer (2019)A de Juan, A Redondo, M J Rubio, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2014
A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgeryI Vergote, A Oaknin, J-F Baurain, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 22, 2017
Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical OncologyA Oaknin, R Guarch, P Barretina, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 18, 2017
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical OncologyA Oaknin, R Guarch, P Barretina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2019
A decade of clinical development of PARP inhibitors in perspectiveJ Mateo, C J Lord, V Serra, et al.
Investigational New Drugs|January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumorsC Massard, R Salazar, J P Armand, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 10, 2015
SEOM guidelines for cervical cancerA Oaknin, M J Rubio, A Redondo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upA González-Martín, P Harter, A Leary, et al.
Pageof 3